After completion of the field sampling and analyses of the samples from the original 12 cities, the data set was not equally populated (25% per cell), but heavy on the non-smoking home/nonsmoking workplace data (Cell 4) with 686 (57%) subjects, and light on the smoking home/smoking workplace (Cell 1) with only 136 subjects (11%).
After completion of the blood sample collection, DNA extraction was started from white blood cells.
After completion of the pharmacokinetic sampling, treatment continued with rubitecan given orally at a dose of 1.5 mg/m2/day, to be increased up to 2.0 mg/m2/day, under fasting conditions for 5 consecutive days per week until disease progression.
After completion of the study, samples were packed and shipped on dry ice to MRC Human Nutrition Research, Cambridge for analysis.
After completion of the amplification, samples were subjected to a temperature ramp (from the annealing temperature to 95°C with a transition rate of 0.1°C/s) with continuous fluorescence monitoring for melting curve analysis.
After completion of the reactions, the samples were heated to 100°C and centrifuged.
After completion of the freezing process, samples were stored in a LN tank.
After completion of the study, PBMC samples were thawed and analyzed simultaneously by staining with peptide-MHC tetramer-APC or PE (25 50 ug/ml), anti-CD8-PE-Cy7, anti-CD3PE or APC, and "dump" antibodies.
After completion of the study, all samples were transferred on dry ice to the Department of Clinical Pharmacology, Bangkok, Thailand for drug quantification.
After completion of the cycling process, samples were immediately subjected to a temperature ramp for melting curve analysis.
